THE TAPE

Medpace Holdings, Inc. Common Stock

$648.20▼ −0.88%
Last close
Relative strength
81RS
of 99, against every stock▲ +5 on the month
Powering up
Unconfirmed
+53.8%
six months against the S&P 500
52-week range
−6.6%
from the high
$373.00$693.97
Setup
On no screen
No base, flag or squeeze in place tonight. What is and is not there
No report date on the calendar.
Growth FLATProof PENDING
Quarter to Sep 30, revenue +9% on a year ago
Why it is on no screen

MEDP is off the screens on one check: shallow enough.

A base has formed24.0 weeks, from 373.00 to 605.25.
Long enough to count24.0 weeks against 3 needed.
Shallow enough38.4% deep against 35% allowed.
Close to its pivot+7.1% from the pivot; listed down to -20%.
Relative strengthRS 81 against 70 needed.

Measured against the base-and-breakout thresholds. The other screens use their own numbers, so a name can miss here and still be a fair-looking chart.

Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
Support and resistance
Support below
$633.89
-2.2% · tested 8× · last 7 sessions ago
Resistance above
$679.57
+4.8% · tested 4× · last 5 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

Medpace Holdings, Inc. Common Stock is not on any of the screens right now. Its relative strength rating is 81, and it sits in Commercial Physical & Biological Research.

Against its industry
UnconfirmedNone of the patterns above holds.
One month against the S&P 500
+8.1%
Three months against the S&P 500
+13.9%
Six months against the S&P 500
+53.8%

Its industry has too few members to make an index of, so it is read against the S&P 500 and can only be turning, caution or unconfirmed.

Peers
Same theme
No themes — common and fine.
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 16.9% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$2.8B
+8.5% year on year
Operating margin
21.4%
Net margin
18.2%
Free cash flow
$667.6M
3.7% of market cap
Price to sales
6.39×
Price to earnings
35.0×

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Oct 21
Key takeaway
Profitable and cash generating; the question is growth.
Revenue
$716.0M
+1.2% QoQ · +8.5% YoY
Gross margin
—
Net income
$137.5M
Positive
Free cash flow
$196.4M
Cash generating

What the numbers say

  • Revenue +8.5% year over year, +1.2% on the quarter
  • Good: Profitable: net income $137M, operating margin 23.1%
  • Good: Cash generating: operating cash flow $217M, free cash flow $196M
  • Good: Net cash $705M · cash $705M
Revenue by quarter
Free cash flow
Net income
shares -1.5% in a year · net cash $705.3M

What is not obvious

  • Weak: Cash flow quality: operating cash flow $217M included a $57M deferred-revenue inflow; $159M without it. Customers paid ahead of delivery
  • Contracted backlog (remaining performance obligations) $3.80B, 1.3× trailing revenue, +9% on the quarter. Backlog is not recognised revenue
Final read
Growth: FLAT · Economic proof: PENDING
Key question: Does the cash flow hold without the deferred revenue and stock pay behind it?
The next test is whether the quarter repeats.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 2 of 46 tracked funds at the end of Q3 2026.

Last quarter: 1 added, 1 trimmed, 1 sold out.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
Reported resultsFiling · 2026-10-22
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
New 52-week highTape · 2026-10-22
3.9x vol
Mixed: stocks have lagged random stocks by 0.9% over three sessions, not consistently enough to call (554 cases over 52 nights). Against their own sector they have lagged by 2.1%.
GappedTape · 2026-10-22
+6.4%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Unusual volumeTape · 2026-10-22
3.7 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.
Earnings comingEvent · 2026-10-20
reports 2026-10-21 amc
No measurable effect: stocks behave like random ones over the next three sessions (2,970 cases over 40 nights).
Several insiders soldInsider · 2026-09-26
2 insiders sold $99,630,469
No measurable effect: stocks behave like random ones over the next three sessions (653 cases over 60 nights).
Several insiders soldInsider · 2026-09-25
2 insiders sold $82,195,668
No measurable effect: stocks behave like random ones over the next three sessions (653 cases over 60 nights).
Several insiders soldInsider · 2026-09-24
3 insiders sold $84,321,484
No measurable effect: stocks behave like random ones over the next three sessions (653 cases over 60 nights).

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders
Bought on the open market
0
Sold on the open market
35
$230,229,559 total

Sold: EWALD STEPHEN P, BURWIG SUSAN E, Troendle August J., Kraft Robert O., Brady Kevin M., Carley Brian T, DAVENPORT FRED B JR, McCarthy Cornelius P. III.

Not counted above: 18 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-10-29 EWALD STEPHEN P · General Counsel & Corp. Secy.sell1,245$859,050
2026-10-27 BURWIG SUSAN E · Exec. VP, Operationssell3,940$2,667,380
2026-10-26 BURWIG SUSAN E · Exec. VP, Operationssell16,060$10,872,620
2026-10-26 BURWIG SUSAN E · Exec. VP, Operationsoption exercise328$54,687
2026-10-21 BURWIG SUSAN E · Exec. VP, Operationsoption exercise2,700$450,171
2026-10-12 BURWIG SUSAN E · Exec. VP, Operationsoption exercise3,000$500,190
2026-10-07 BURWIG SUSAN E · Exec. VP, Operationsoption exercise2,000$333,460
2026-09-30 McCarthy Cornelius P. III · Directoroption exercise28

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What analysts expect
Strong buy1
Buy1
Hold11
Sell1
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray

No completed base to compare this one with yet.

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Medpace Holdings, Inc. Common Stock (MEDP) — The Tape